SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

10-Q - Keen Vision Acquisition Corp. (0001889983) (Filer)

SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)

DEF 14A - Keen Vision Acquisition Corp. (0001889983) (Filer)

8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)

PRE 14A - Keen Vision Acquisition Corp. (0001889983) (Filer)

8-K - Keen Vision Acquisition Corp. (0001889983) (Filer)

10-Q - Keen Vision Acquisition Corp. (0001889983) (Filer)

SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatmentsPartnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapiesLeveraging Novoheart's proprietary mini-Heart Platform, this partnership aligns with emerging FDA guidelines supporting human-relevant, animal-free drug development BOSTON and SAN DIEGO and ROCHESTER, Minn., June 24, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical com

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA. Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFp

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF is a prevalent form of heart disease that accounts for half of an estimated 64.3

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF). HErEF is a prevalent form of heart disease that accounts for half of an estimated 64.3 million heart failure cases worldwide and is currently considered a mass market incurable disease. The MUSIC-HFrEF trial is an open-label, uncontrolled st

Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac disease modeling and therapeutic screening, including both drug candidates and gene editing approachesDriving Innovation: This installation paves the way for future co-development projects with UMC Utrecht, advancing human-based research and cardiac regenerative technologies BOSTON and UTRECHT, Netherlands, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant

SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., ("Medera"), a clinical-stage biotechnology company, announced today that the management team will participate in the two upcoming investor conferences in February 2025 as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference: presentation at 10:40 am ET on February 11th and available to host investor meetingsBIO CEO & Investor Conference: available for meetings on February 10th and 11th A live audio webcast of the presentation at the Oppenheimer conference will be accessible at the following link (https://wsw.com/webcast/oppenheimer39/medera/3197872). A replay of the webcast will be accessible for 30

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart's human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio's cloud-based Pulse™ analytics, enabling smart and accelerated cardiac drug screening.Industry-First Capabilities Combined: Medera's Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and FTD applications. As a pioneer in pre-clinical screening, Curi Bio has advanced cloud-based data analysis tools.Accelerated Drug Development: With newly introduced technologies, the combined platform is expected to increase e

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing protocols, setting a new benchmark for human-based cardiac screeningLatest enhanced 96-well technology enables rapid, high-throughput screening on bioengineered human heart tissues, with significant cost and efficiency gains BOSTON and GOTHENBURG, Sweden, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, and Novoheart, its wholly owned pre-clinical sub

Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costsHuman-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancementsThis new study leverages the capabilities of artificial intelligence (AI) and machine learning (ML) to address the challenge of achieving automated and comprehensive "smart" drug screening using Medera's mini-Heart technology platformInnovative AI/ML-based model combines data from multiple human mini-Heart screening assays and takes advantage of the complementary strengths to achieve superior next-generation

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per yearHeart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeuticsPromising efficacy results in cardiovascular performance observed in Cohort A (low-dose SRD-002) at six months with additional data being collectedInitiated dosing patients in Cohort B (high-dose SRD-002) following recommendation of the DSMBSUMMIT, N.J. and BOSTON, Oct. 24, 2024 /PRNewswire/ -- Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-

SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

SC 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)